|1.||Levy, David E: 5 articles (11/2011 - 02/2002)|
|2.||Wasiewski, Warren W: 3 articles (12/2009 - 01/2009)|
|3.||Demchuk, Andrew M: 2 articles (12/2009 - 05/2009)|
|4.||Demaerschalk, Bart M: 2 articles (12/2009 - 05/2009)|
|5.||Pancioli, Arthur M: 2 articles (12/2009 - 05/2009)|
|6.||del Zoppo, Gregory J: 2 articles (12/2009 - 05/2009)|
|7.||Kaste, Markku: 2 articles (12/2009 - 05/2009)|
|8.||Trammel, James: 2 articles (05/2009 - 01/2009)|
|9.||Müller-Peltzer, H: 2 articles (12/2001 - 10/2000)|
|10.||Rübsamen, K: 2 articles (12/2001 - 10/2000)|
01/01/1985 - "After ancrod, striking resolution of microvascular thrombosis occurred, which was associated with some improvement in renal function and blood pressure control. "
01/15/1996 - "The effect of ancrod-induced defibrinogenation on thrombosis and bleeding time was determined in anesthetized rats. "
02/01/1995 - "Enhancement of plasma fibrinolytic activity by ancrod had no influence on thrombus lysis and was not all affected by administration of D370.(ABSTRACT TRUNCATED AT 250 WORDS)"
02/01/1995 - "In order to provide further support for such a mechanism, we exploited the defibrinating capacity of ancrod to obtain a thrombosis model characterized by the lack of thrombus growth and thus sensitive only to agents promoting thrombus lysis. "
04/01/1994 - "Ancrod provides a reasonable therapeutic option if thrombosis does occur."
09/01/1994 - "Ancrod appears safe and potentially effective when administered to patients within 6 hours of onset of ischemic stroke."
05/01/1990 - "The biological effect of fibrinolysis in ancrod infused patients was demonstrated by a greater improvement in stroke score when compared to those infused with saline."
01/01/1997 - "These activities suggest that treating patients with acute ischaemic stroke with ancrod might result in improved cerebral blood flow and patient outcome. "
09/01/1994 - "We studied the safety and efficacy of ancrod in patients with acute ischemic stroke administered within 6 hours of stroke onset. "
12/01/2009 - "Five hundred subjects with acute ischemic stroke who could begin receiving study material within 6 hours of symptom onset were infused intravenously with either ancrod (0.167 IU/kg per hour) or placebo over 2 or 3 hours. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1987 - "Defibrination with ancrod is effective in prevention and treatment of venous thrombosis but its role in arterial disease is unproven. "
12/01/1990 - "The rheologic blood properties were studied in patients with acute venous thrombosis during Arvin therapy. "
01/01/1982 - "Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery."
10/01/1978 - "Prevention of deep vein thrombosis by subcutaneous ancrod."
10/19/1974 - "Though the incidence of deep vein thrombosis was not apparently affected by ancrod it appeared on venography that the thrombi in the treated patients were less extensive than those in the control patients. "
12/01/1991 - "Nurses must assess ancrod study patients for potential bleeding problems. "
01/01/1998 - "In contrast, significant reductions in the volumes of ICH were observed suggesting favorable influence of ancrod in the event of intracranial bleeding in rats."
01/01/1998 - "Because ancrod has been shown to produce rapid defibrinogenation, we investigated the effects of this agent in a rat model of intracranial bleeding using noninvasive magnetic resonance imaging (MRI). "
08/01/1997 - "None of the ancrod-treated rats showed evidence of intracerebral bleeding on T2-weighted magnetic resonance images taken after 24 h. "
09/01/1994 - "No increase in bleeding occurred in the ancrod-treated patients. "
|5.||Wounds and Injuries (Trauma)
03/01/1989 - "The healing rate was 1.24 +/- 0.41 mm2/hr in ancrod-treated corneal wounds and 1.19 +/- 0.29 mm2/hr in control eyes during the first 48 hr after wounding (P greater than 0.5). "
03/01/1989 - "(2) In a rabbit epithelial scrape wound model, ancrod was administered intravenously to induce systemic Fg depletion. "
08/01/1976 - "Although the ancrod was effective in preventing arterial thrombosis, 88% of the wounds showed moderate to severe separations. "
01/01/1982 - "Four patients within the ancrod group had evidence of wound bleeding, compared with 2 placebo patients. "
01/01/1981 - "Systemic defibrinogenation using Arvin delays wound strength development and collagen accumulation in sponge-induced granulation tissue. "
|2.||Fibrinogen (Factor I)
|10.||Crotalid Venoms (Rattlesnake Venom)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Cardiopulmonary Bypass (Heart-Lung Bypass)